Second-generation vaccines against leishmaniasis

被引：192

作者：

Coler, RN

Reed, SG

机构：

[1] Infect Dis Res Inst, Seattle, WA 98104 USA

[2] TheraVax, Seattle, WA 98104 USA

来源：

TRENDS IN PARASITOLOGY | 2005年 / 21卷 / 05期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/j.pt.2005.03.006

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

Several species of Leishmania cause human diseases that range from self-healing cutaneous lesions to fatal visceral leishmaniasis, mucosal leishmaniasis and diffuse cutaneous leishmaniasis. Drug resistance and toxicities associated with chemotherapy emphasize the need for a safe, effective vaccine. Studies of the immunopathogenesis and mechanisms of protective immunity define several features that should be met by an effective vaccine. The leishmaniases are unique among parasitic diseases because a single vaccine has the potential to protect against more than one species (disease) and be successful at both treating and preventing disease. In addition, several antigens have been identified and characterized that might be potential vaccine candidates. In this article, we focus on advances made with second-generation vaccines against leishmaniasis.

引用

收藏

页码：244 / 249

页数：6

相关论文

共 60 条

[1] Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants [J].

Aebischer, T ;

Wolfram, M ;

Patzer, SI ;

Ilg, T ;

Wiese, M ;

Overath, P .

INFECTION AND IMMUNITY, 2000, 68 (03) :1328-1336

[2] THE ADJUVANT EFFECT OF INTERLEUKIN-12 IN A VACCINE AGAINST LEISHMANIA-MAJOR [J].

AFONSO, LCC ;

SCHARTON, TM ;

VIEIRA, LQ ;

WYSOCKA, M ;

TRINCHIERI, G ;

SCOTT, P .

SCIENCE, 1994, 263 (5144) :235-237

[3]

Badaro R, 2001, Braz J Infect Dis, V5, P223

[4] Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2 [J].

Becker, I ;

Salaiza, N ;

Aguirre, M ;

Delgado, J ;

Carrillo-Carrasco, N ;

Kobeh, LG ;

Ruiz, A ;

Cervantes, R ;

Torres, AP ;

Cabrera, N ;

González, A ;

Maldonado, C ;

Isibasi, A .

MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2003, 130 (02) :65-74

[5] CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity [J].

Belkaid, Y ;

Piccirillo, CA ;

Mendez, S ;

Shevach, EM ;

Sacks, DL .

NATURE, 2002, 420 (6915) :502-507

[6] Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein [J].

Borges, MM ;

Campos-Neto, A ;

Sleath, P ;

Grabstein, KH ;

Morrisey, PJ ;

Skeiky, YAW ;

Reed, SG .

INFECTION AND IMMUNITY, 2001, 69 (09) :5270-5277

[7] MOLECULAR CHARACTERIZATION OF A KINESIN-RELATED ANTIGEN OF LEISHMANIA-CHAGASI THAT DETECTS SPECIFIC ANTIBODY IN AFRICAN AND AMERICAN VISCERAL LEISHMANIASIS [J].

BURNS, JM ;

SHREFFLER, WG ;

BENSON, DR ;

GHALIB, HW ;

BADARO, R ;

REED, SG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :775-779

[8] Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice [J].

Campos-Neto, A ;

Webb, JR ;

Greeson, K ;

Coler, RN ;

Skeiky, YAW ;

Reed, SG .

INFECTION AND IMMUNITY, 2002, 70 (06) :2828-2836

[9] Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease [J].

Campos-Neto, A ;

Porrozzi, R ;

Greeson, K ;

Coler, RN ;

Webb, JR ;

Seiky, YAW ;

Reed, SG ;

Grimaldi, G .

INFECTION AND IMMUNITY, 2001, 69 (06) :4103-4108

[10] MEMBRANE GLYCOPROTEIN M-2 PROTECTS AGAINST LEISHMANIA-AMAZONENSIS INFECTION [J].

CHAMPSI, J ;

MCMAHONPRATT, D .

INFECTION AND IMMUNITY, 1988, 56 (12) :3272-3279

← 1 2 3 4 5 6 →